Evidence mapPaperPMID 41667033Full record

ArticleJournal of molecular and cellular cardiology2026

Coronary artery disease risk gene PRDM16 regulates smooth muscle homeostasis.

Kunzhe Dong, Yingbing Zuo, Yali Yao, Xiangqin He, Guoqing Hu, Xiaoping Peng, Jiliang Zhou

Abstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kunzhe DongImmunology Center of Georgia, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pharmacology & Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. Electronic address: kdong@augusta.edu.
Yingbing ZuoImmunology Center of Georgia, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China.
Yali YaoImmunology Center of Georgia, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Xiangqin HeDepartment of Pharmacology & Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pathology and Translational Pathobiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Guoqing HuDepartment of Pharmacology & Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Xiaoping PengDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China; Jiangxi Hypertension Research Institute, Nanchang, Jiangxi 330006, China; Jiangxi Key Laboratory of Neurological Diseases, Department of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China.
Jiliang ZhouDepartment of Pharmacology & Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA. Electronic address: jiliang.zhou@lsuhs.edu.

Funding

PIK3C3, a master regulator for smooth muscle identityR01HL157568 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · 2023 to 2025
$2.0M
Posttranslational control of VSMC identity and vascular healthR01HL179809 · AUGUSTA UNIVERSITY · 2025 to 2025
$767k
The uncharacterized nuclear protein HMGXB4 in occlusive vascular diseasesK99HL171834 · AUGUSTA UNIVERSITY · 2025 to 2025
$133k
NHLBI NIH HHS K99 HL171834NHLBI NIH HHS R01 HL157568NHLBI NIH HHS R01 HL179809
6 · The paper itself

Abstract

objectiveVascular smooth muscle cells (VSMCs) are the primary contractile component of blood vessels and can undergo phenotypic switching from a contractile to a synthetic phenotype in vascular diseases such as coronary artery disease (CAD) and restenosis. This process leads to decreased expression of SMC lineage genes and increased proliferative, migratory and secretory abilities that drive disease progression. Super-enhancers (SE) and lineage-specific transcription factors are believed to drive expression of genes that maintain cell identity and homeostasis. The goal of this study is to identify novel regulators of VSMC homeostasis by screening for SE-regulated transcription factors in arterial tissues. APPROACH AND

resultsWe characterized human artery SEs by analyzing the enhancer histone mark H3K27ac ChIP-seq data of multiple arterial tissues. We unexpectedly discovered the transcription factor PRDM16, a GWAS-identified CAD risk gene with previously well-documented roles in brown adipocytes but with an unknown function in vascular disease progression, is enriched with artery-specific SEs. Further analysis of public bulk RNA-seq and scRNA-seq datasets, as well as qRT-PCR and Western blotting analysis, demonstrated that PRDM16 is highly expressed in arterial tissues and in contractile VSMCs but not in visceral SMCs, and down-regulated in phenotypically modulated VSMCs. To explore the function of Prdm16 in vivo, we generated both inducible and constitutive Prdm16 SMC-specific knockout mice and performed bulk RNA-Seq analysis of aortic tissues and left carotid artery ligation to assess neointima formation. SMC-deficiency of Prdm16 does not affect the aortic morphology at baseline but significantly alters expression of many genes involved in VSMC homeostasis and cardiovascular disease, and suppresses VSMC proliferation and neointima formation in male mice. Specifically, Prdm16 negatively regulates the expression of Tgfb2 that encodes an upstream ligand of the TGF-β signaling pathway, by suppressing its promoter activity.

conclusionsOur results suggest that the CAD risk gene PRDM16 is highly expressed in VSMCs and is a novel regulator of VSMC homeostasis and neointima formation.

Indexed as

Coronary Artery DiseaseDNA-Binding ProteinsGenetic Predisposition to DiseaseHomeostasisMuscle, Smooth, VascularTranscription FactorsAnimalsGene Expression RegulationHumansMaleMiceMyocytes, Smooth MuscleSuper EnhancersDNA-Binding ProteinsPRDM16 protein, humanPrdm16 protein, mouseTranscription FactorsCoronary artery diseaseNeointima formationPRDM16Smooth muscle cellsSuper enhancers

Identifiers

PMID41667033
PMCPMC13215035

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.